The objective of this study is to explore the efficacy and safety of rivaroxaban 20 mg once daily ( 15 mg if creatinine clearance is 30-49 mL/min ) compared with dose-adjusted vitamin K antagonists ( VKAs ; international normalized ratio 2.0-3 .0 ) in patients scheduled for elective cardioversion .